Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned

After more than one year of the COVID-19 pandemic, antiviral treatment options against SARS-CoV-2 are still severely limited. High hopes that had initially been placed on antiviral drugs like remdesivir have so far not been fulfilled. While individual case reports provide striking evidence for the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dölken, Lars, Stich, August, Spinner, Christoph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224666/
https://www.ncbi.nlm.nih.gov/pubmed/34067381
http://dx.doi.org/10.3390/v13060963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224666/
https://www.ncbi.nlm.nih.gov/pubmed/34067381
http://dx.doi.org/10.3390/v13060963

Ejemplares similares